Print this page
A Phase I Study of Autophagy Inhibition with Hydroxychloroquine and Oral Decitabine with Venetoclax after Hypomethylating Agent and Venetoclax Failure in Acute Myeloid Leukemia.
Phase I:
Primary Objective:
- Determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of the o-Dec, ven, and HCQ
Secondary Objectives:
- Characterize the safety profile of the triplet
- Estimate the efficacy of the combination to induce remission
Protocol Number:
022601
Phase:
Phase I
Applicable Disease Sites:
Leukemia, not otherwise specified
Leukemia, other
Leukemia, other
Drugs Involved:
Decitabine (Dacogen)
Hydroxychloroquine
Venetoclax (ABT-199)
Hydroxychloroquine
Venetoclax (ABT-199)
Principal Investigator:
Neil Palmisiano
Scope:
Local
Therapies Involved:
Chemotherapy multiple agents systemic
Participating Institutions:
- RWJBarnabas Health
- Monmouth Medical Center
- Rutgers University
For further information about clinical trials, please contact us at 732-235-7356.